Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress
May 24, 2024 07:00 ET
|
Bio-Path Holdings, Inc.
HOUSTON, May 24, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop...
Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
May 23, 2024 21:03 ET
|
Adlai Nortye Ltd.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology...
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
May 23, 2024 20:00 ET
|
HUTCHMED (China) Limited
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from...
LexinFintech Holdings Ltd. Reports First Quarter 2024 Unaudited Financial Results
May 23, 2024 19:00 ET
|
LexinFintech Holdings Ltd.
SHENZHEN, China, May 23, 2024 (GLOBE NEWSWIRE) -- LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading technology-empowered personal financial service enabler in China,...
Huize Holding Limited Reports First Quarter 2024 Unaudited Financial Results
May 23, 2024 18:00 ET
|
Huize Holding Limited
SHENZHEN, China, May 23, 2024 (GLOBE NEWSWIRE) -- Huize Holding Limited, (“Huize”, the “Company” or “we”) (NASDAQ: HUIZ), a leading insurance technology platform connecting consumers, insurance...
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
May 23, 2024 18:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, May 23, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and its collaborators will share data from seven studies...
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 17:51 ET
|
Coherus BioSciences, Inc.
CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T...
CORRECTION – The Herzfeld Caribbean Basin Fund, Inc. Announces Distribution in Stock and Cash
May 23, 2024 17:49 ET
|
Herzfeld Caribbean Basin Fund
MIAMI BEACH, Fla., May 23, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by The Herzfeld Caribbean Basin Fund, Inc. (NASDAQ: CUBA) (the “Fund”), please note that...
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
May 23, 2024 17:30 ET
|
Elicio Therapeutics, Inc.
ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levelsELI-002 7P generated an mKRAS-specific T...
Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq
May 23, 2024 17:18 ET
|
Fresh2 Group Ltd
New York, NY, May 23, 2024 (GLOBE NEWSWIRE) -- Fresh2 Group Ltd. (NASDAQ: FRES) (“Fresh2” or the “Company”), a B2B e-commerce and supply chain management company within the restaurant and food...